Coumarin-Augmented Thiazole Hybrids as Dual Anticancer and Antibacterial Agents.

Islam K Matar, Magdi E A Zaki, Zeinab A Muhammad, Dahlia A Awwad, Sami A Al-Hussain, Chérif F Matta, Refaie M Kassab

Abstract read

In one paragraph

Article in Chemical biology & drug design, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it

0cells of the map it votes in

0citing papers in PubMed

–field-weighted citation impact

1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Islam K MatarDepartment of Chemistry, Saint Mary's University, Halifax, Nova Scotia, Canada.ORCID https://orcid.org/0000-0001-5997-2574

Magdi E A ZakiDepartment of Chemistry, Faculty of Science, Imam Mohammad Ibn Saud Islamic University (IMSIU), Riyadh, South Africa.ORCID https://orcid.org/0000-0002-5643-9202

Zeinab A MuhammadDepartment of Pharmaceutical Chemistry, Egyptian Drug Authority (EDA), Giza, Egypt.ORCID https://orcid.org/0000-0003-1711-8497

Dahlia A AwwadUniversity of Science and Technology (UST), Zewail City of Science and Technology, Giza, Egypt.

Sami A Al-HussainDepartment of Chemistry, Faculty of Science, Imam Mohammad Ibn Saud Islamic University (IMSIU), Riyadh, South Africa.

Chérif F MattaDepartment of Chemistry, Saint Mary's University, Halifax, Nova Scotia, Canada.ORCID https://orcid.org/0000-0001-8397-5353

Refaie M KassabDepartment of Chemistry, Faculty of Science, Cairo University, Giza, Egypt.

Funding

Imam Mohammad Ibn Saud Islamic University IMSIU-DDRSP2501

6 · The paper itself

Abstract

Coumarins are a privileged scaffold in medicinal chemistry, renowned for diverse therapeutic activities including antiviral, anticancer, and neuroprotective effects. Building on our previous work with 3-substituted coumarins as inhibitors of tumor-associated carbonic anhydrases, we report a novel series of thiazol-hydrazono-coumarins targeting the ATP-binding domain of topoisomerase enzymes. Seventeen compounds were synthesized and evaluated for selective cytotoxicity against HeLa cells versus WI-38 fibroblasts and for antimicrobial activity against four ESKAPE pathogens, Escherichia coli, and Salmonella typhimurium. Several derivatives showed potent antibacterial activity, with MICs as low as 0.12 μg/mL against resistant Staphylococcus aureus strains and inhibition zones up to 33 mm against Gram-negative bacteria. Compound 13 exhibited strong selectivity, with an IC

Indexed as

Anti-Bacterial AgentsAntineoplastic AgentsCoumarinsThiazolesBinding SitesDNA GyraseDNA Topoisomerase IVEscherichia coliHeLa CellsHumansMicrobial Sensitivity TestsMolecular Docking SimulationMolecular Dynamics SimulationSalmonella typhimuriumStaphylococcus aureusTopoisomerase II InhibitorsAnti-Bacterial AgentsAntineoplastic AgentscoumarinCoumarinsDNA GyraseDNA Topoisomerase IVThiazolesTopoisomerase II Inhibitorsantibacterial activityanticancer agentscoumarin derivativesDNA gyrase B inhibitorstopoisomerase II inhibitors

Identifiers

PMID41721470

DOI10.1111/cbdd.70261

PMCPMC12923669

What OpenQuestion holds

Textmetadata

LicenceCC BY

Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.